Literature DB >> 1416823

Therapy of Rhodococcus equi disseminated infections in nude mice.

P Nordmann1, J J Kerestedjian, E Ronco.   

Abstract

Rhodococcus equi is a facultative, intracellular, gram-positive coccobacillus increasingly reported as an opportunistic pathogen in human immunodeficiency virus-positive patients. However, the optimal drug regimen for treating R. equi pulmonary or systemic infections is not yet known. Therefore, a model of intravenously infected nude mice with disseminated infection was created to study the efficacy of antibiotics alone or in combination as determined by the reduction of bacterial CFU per gram in the lungs and spleen after 4 and 11 days of treatment. The studied antibiotics possessing low MICs against R. equi strains were amikacin, ciprofloxacin, erythromycin, imipenem, minocycline, rifampin, and vancomycin. Vancomycin, imipenem, and rifampin were the most effective agents in monotherapy. On the other hand, amikacin, ciprofloxacin, erythromycin, and minocycline alone were not active in this model. The most active drug combinations were those including vancomycin. No antibiotic-resistant mutants were selected in vivo with treatment involving any drugs used alone or in combination. Although the treatment recommended until now for R. equi infections is rifampin plus erythromycin, this study suggests that antibiotic combinations which include vancomycin may be the most effective in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1416823      PMCID: PMC190326          DOI: 10.1128/AAC.36.6.1244

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Drug therapy. Clinical Pharmacokinetics (first of two parts).

Authors:  D J Greenblatt; J Kock-Weser
Journal:  N Engl J Med       Date:  1975-10-02       Impact factor: 91.245

2.  In-vitro susceptibility of Rhodococcus equi to 27 antibiotics.

Authors:  D Decré; A Buré; B Pangon; A Phillippon; E Bergogne-Bérézin
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790

3.  [Electronmicroscopical hepatic findings in experimental listeriosis].

Authors:  L Cossel; P F Mahnke
Journal:  Beitr Pathol Anat       Date:  1968

4.  Use of erythromycin-rifampin combination in treatment of Rhodococcus equi pneumonia.

Authors:  C J Hillidge
Journal:  Vet Microbiol       Date:  1987-08       Impact factor: 3.293

5.  The inhibitory quotient. A method for interpreting minimum inhibitory concentration data.

Authors:  P D Ellner; H C Neu
Journal:  JAMA       Date:  1981-10-02       Impact factor: 56.272

6.  Corynebacterium equi: in vitro susceptibility to twenty-six antimicrobial agents.

Authors:  J B Woolcock; M D Mutimer
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

Review 7.  Rhodococcus equi infection in patients with and without human immunodeficiency virus infection.

Authors:  R L Harvey; J C Sunstrum
Journal:  Rev Infect Dis       Date:  1991 Jan-Feb

8.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

9.  Corynebacterium equi: a review of 12 cases of human infection.

Authors:  L L Van Etta; G A Filice; R M Ferguson; D N Gerding
Journal:  Rev Infect Dis       Date:  1983 Nov-Dec

10.  [Rhodococcus equi infection in HIV disease].

Authors:  M Flepp; R Lüthy; J Wüst; W Steinke; P Greminger
Journal:  Schweiz Med Wochenschr       Date:  1989-05-06
View more
  17 in total

1.  The equine antimicrobial peptide eCATH1 is effective against the facultative intracellular pathogen Rhodococcus equi in mice.

Authors:  Margot Schlusselhuber; Riccardo Torelli; Cecilia Martini; Matthias Leippe; Vincent Cattoir; Roland Leclercq; Claire Laugier; Joachim Grötzinger; Maurizio Sanguinetti; Julien Cauchard
Journal:  Antimicrob Agents Chemother       Date:  2013-07-01       Impact factor: 5.191

2.  Activity of clarithromycin or rifampin alone or in combination against experimental Rhodococcus equi infection in mice.

Authors:  Alexandra J Burton; Steeve Giguère; Londa J Berghaus; Mary K Hondalus
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

3.  Characterization of mutations in the rpoB gene associated with rifampin resistance in Rhodococcus equi isolated from foals.

Authors:  M Fines; S Pronost; K Maillard; S Taouji; R Leclercq
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

Review 4.  Intracellular concentrations of antibacterial agents and related clinical implications.

Authors:  J D Butts
Journal:  Clin Pharmacokinet       Date:  1994-07       Impact factor: 6.447

5.  PNAG-specific equine IgG1 mediates significantly greater opsonization and killing of Prescottella equi (formerly Rhodococcus equi) than does IgG4/7.

Authors:  Joana N Rocha; Lawrence J Dangott; Waithaka Mwangi; Robert C Alaniz; Angela I Bordin; Colette Cywes-Bentley; Sara D Lawhon; Suresh D Pillai; Jocelyne M Bray; Gerald B Pier; Noah D Cohen
Journal:  Vaccine       Date:  2019-01-26       Impact factor: 3.641

6.  In vivo efficacies of combinations of beta-lactams, beta-lactamase inhibitors, and rifampin against Acinetobacter baumannii in a mouse pneumonia model.

Authors:  M Wolff; M L Joly-Guillou; R Farinotti; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1999-06       Impact factor: 5.191

7.  Recurrent Rhodococcus equi infection with fatal outcome in an immunocompetent patient.

Authors:  P Gabriels; H Joosen; E Put; J Verhaegen; K Magerman; R Cartuyvels
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2006-01       Impact factor: 3.267

8.  Failure of pulmonary clearance of Rhodococcus equi infection in CD4+ T-lymphocyte-deficient transgenic mice.

Authors:  S T Kanaly; S A Hines; G H Palmer
Journal:  Infect Immun       Date:  1993-11       Impact factor: 3.441

9.  Correlation between antibiotic resistance, phage-like particle presence, and virulence in Rhodococcus equi human isolates.

Authors:  P Nordmann; M Keller; F Espinasse; E Ronco
Journal:  J Clin Microbiol       Date:  1994-02       Impact factor: 5.948

Review 10.  The medically important aerobic actinomycetes: epidemiology and microbiology.

Authors:  M M McNeil; J M Brown
Journal:  Clin Microbiol Rev       Date:  1994-07       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.